Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CHEK vs GEHC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GEHC Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

GEHC Overall Winner 6-Pillar Tally: CHEK 0 – 6 GEHC Matrix Metrics: CHEK 1 – 9 GEHC

As of Nov 20, 2026, GE HealthCare Technologies Inc. (GEHC) is the stronger overall head-to-head candidate over Check-Cap Ltd. (CHEK) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CHEK carries a Unified Composite Score of 52.1/100 (HOLD) at $1.61 (N/M Forward P/E, 0.0% operating margin), whereas GEHC carries 38.6/100 (SELL) at $80.64 (14.7x Forward P/E, 13.8% operating margin).

  • Composite vs. Pillar Nuance: While CHEK currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. GEHC 38.6/100 SELL), GEHC captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (13.8% vs. 0.0% operating margin) and revenue trajectory (+7.2% vs. +0.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CHEK vs GEHC
CHEK NASDAQ
Check-Cap Ltd.
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$1.61
+1.9% 1D
Market Cap $9.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.94β · 179% Vol
Unified Composite Score
52.1 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 51.0 · SMA20: $1.52 · SMA50: $1.80
GEHC NASDAQ Head-to-Head Winner
GE HealthCare Technologies Inc. Common Stock
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$80.64
-1.53% 1D
Market Cap $37.0B
TTM Revenue $21.6B
Forward P/E 14.7x
Beta / 30D Vol 0.52β · 39% Vol
Unified Composite Score
38.6 / 100 SELL
Tech 29.0 Fund 44.0 Flow 59.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.6% over 20 days), RSI 56
RSI-14: 56.4 · SMA20: $80.51 · SMA50: $72.19

6-Pillar Scorecard Institutional Category Breakdown (CHEK 0 – 6 GEHC)

Columns: Metric · CHEK · GEHC
1. Valuation Multiples GEHC
Forward P/E N/M 14.7x
Trailing P/E N/M 17.3x
PEG Ratio N/M 2.24x
EV / Revenue N/M 2.1x
2. Growth & Scale GEHC
Revenue Growth (YoY) +0.0% +7.2%
Earnings Growth (YoY) +0.0% +39.0%
TTM Revenue (USD) N/A $21.6B
Market Cap $9.2M $37.0B
3. Profitability & Quality GEHC
Gross Margin N/A 39.3%
Operating Margin 0.0% 13.8%
Net Profit Margin 0.0% 10.0%
Return on Equity (ROE) -226.2% 20.0%
4. Balance Sheet & Cash Flow GEHC
Cash Generation (TTM) N/A $1.89B
Cash Flow Margin N/A 8.7%
Net Cash / Leverage -226.2% ROE $7.58B Net Debt (0.90x D/E)
Dividend Yield None (0.00%) 0.17%
5. Options & Positioning GEHC
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile N/A (N/A) 58.6% (8th %ile)
Put/Call OI Skew N/A 0.28x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat GEHC
OpEx & R&D Intensity N/A 25.5% of Rev ($5.52B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role X-Ray Apparatus & Tubes & Related Irradiation Apparatus Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CHEK (1) vs GEHC (9)
Institutional Metric CHEK GEHC Criterion Row Edge
Market Capitalization
Scale
$9.2M $37.0B Larger Scale GEHC
Trailing P/E Ratio
Valuation
N/M 17.3x Lower Multiple GEHC
Forward P/E Ratio
Valuation
N/M 14.7x Lower Multiple GEHC
Revenue Growth (YoY)
Growth
+0.0% +7.2% Higher Growth GEHC
Operating Margin (TTM)
Profitability
0.0% 13.8% Higher Margin GEHC
Net Profit Margin
Profitability
0.0% 10.0% Higher Margin GEHC
Return on Equity (ROE)
Capital Efficiency
-226.2% 20.0% Higher ROE GEHC
52-Week Range Position
Momentum
41% ($1–$3) 71% ($59–$90) Stronger Trend GEHC
Beta / 30D Volatility
Risk Regime
0.94β · 179% Vol 0.52β · 39% Vol Lower Realized Risk GEHC
Unified Institutional Score
Composite Signal
52.1 / 100 (HOLD) 38.6 / 100 (SELL) Higher Composite CHEK
Trailing 12M Revenue (USD)
Operating Scale
N/A $21.6B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 39.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 2.24x PEG · 2.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (-226.2% ROE) $1.89B ($7.58B Net Debt (0.90x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GEHC +0.48 pp
CHEK: +11.03% · GEHC: +11.51%
3M Horizon GEHC +0.48 pp
CHEK: +11.03% · GEHC: +11.51%
6M Horizon GEHC +0.48 pp
CHEK: +11.03% · GEHC: +11.51%
1Y Horizon GEHC +0.48 pp
CHEK: +11.03% · GEHC: +11.51%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CHEK vs GEHC. Trailing 12-month operating profitability (CHEK 0.0% vs GEHC 13.8%) and valuation multiples (CHEK N/M vs GEHC 14.7x Forward P/E) are benchmarked directly in Pillar 4 below.

CHEK ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-226.2% · N/M
GEHC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$21.6B
Gross Margin39.3%
Op. Margin13.8%
ROE / Fwd P/E20.0% · 14.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CHEK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CHEK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GEHC SURGE
12d in phase · OBV DISTRIBUTION
Current IV 58.6%
IV Percentile 8th %ile
Put/Call OI Skew 0.28x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact GEHC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $82.96 · IV 29.7%

GEHC Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($8,296)

Compare $8,296 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 29.7% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $82.5 / $87.5 Bull Call Spread

Buy 1x $82.5C · Sell 1x $87.5C · 32d

Net Entry $222 Debit
T+5d @ +5% Move +$109 (+49%)
Max Risk / Buffer $222 Capped
5d Edge & Liquidity 0.8x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $77.5 / $72.5 Bull Put Spread

Sell 1x $77.5P · Buy 1x $72.5P · 32d

Net Entry $87 Credit
Max Credit / Yield +$87 (+21.1% RoM)
Max Risk / Buffer -7.6% Cushion ($413 Mgn)
5d Edge & Liquidity 78% PoP · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CHEK Moat Profile Cyclical / Execution-Driven Positioning
X-Ray Apparatus & Tubes & Related Irradiation Apparatus Operator
Competes within the X-Ray Apparatus & Tubes & Related Irradiation Apparatus value chain with $9.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
GEHC Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $37.0B market capitalization and 13.8% operating margin.
OpEx & R&D Reinvestment 25.5% of Rev ($5.52B)
90D Engineering Disclosures 0 Published

Investor FAQ CHEK vs GEHC Key Questions & Quantitative Answers

As of Nov 20, 2026, GE HealthCare Technologies Inc. (GEHC) is the stronger overall head-to-head candidate over Check-Cap Ltd. (CHEK) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CHEK carries a Unified Composite Score of 52.1/100 (HOLD) at $1.61 (N/M Forward P/E, 0.0% operating margin), whereas GEHC carries 38.6/100 (SELL) at $80.64 (14.7x Forward P/E, 13.8% operating margin). Composite vs. Pillar Nuance: While CHEK currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. GEHC 38.6/100 SELL), GEHC captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (13.8% vs. 0.0% operating margin) and revenue trajectory (+7.2% vs. +0.0% YoY).

GEHC leads the Growth & Scale pillar: CHEK posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with GEHC at +7.2% YoY revenue growth and +39.0% YoY earnings growth on $21.6B TTM revenue (39.3% gross margin, 13.8% operating margin). On trailing 12-month operating scale, CHEK generates N/A in USD-normalized revenue versus $21.6B for GEHC. In operating R&D and SG&A reinvestment, CHEK deploys N/A (0 90-day corporate R&D disclosures) versus 25.5% of Rev ($5.52B) (0 disclosures) for GEHC.

GEHC screens cheaper on headline valuation multiples. CHEK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas GEHC trades at 14.7x Forward P/E, 17.3x Trailing P/E, 2.24x PEG, and 2.1x EV/Revenue (8.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CHEK (-226.2% ROE) versus GEHC (20.0% ROE) capital efficiency.

In options market volatility and institutional positioning, CHEK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.94β · 179% Vol realized risk). By comparison, GEHC carries 58.6% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.28x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.52β · 39% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.